Phyton Biotech, a German/North American Plant Cell Fermentation technology company, and AqVida, a German oncology Finished Dosage Formulation (FDF) manufacturer, have received European approval from the European Directorate of Quality Medicines for AqVida's paclitaxel injectable FDF, it was reported yesterday.
According to the strategic partnership agreement with AqVida, Phyton Biotech will be the exclusive supplier of paclitaxel API for AqVida's Taxol generic formulation, which is produced in AqVida's new state-of-the-art injectable manufacturing facility situated in Dassow, Germany. AqVida's ultra-modern robotic manufacturing line, designed for filling cytotoxic injectables, will be used to produce AqVida's generic oncology medicines to treat common types of cancer.
Wolfgang Heinze, chief executive officer (CEO) of AqVida, said, 'We chose to work with Phyton because of the company's superior quality fermentation-produced API, in comparison to naturally extracted or semi-synthetically produced alternatives. Approval of ourpaclitaxel injectable FDF by the European Directorate of Quality Medicines is a major milestone for our company.'
Apotex launches Teriparatide Injection in US
Teva Pharmaceuticals secures FDA approval for generic Forteo (teriparatide injection)
Upsher-Smith Laboratories introduces Pitavastatin Tablets
Par Pharmaceutical starts shipping colchicine 0.6mg capsules
Padagis launces Brinzolamide Ophthalmic Suspension with CGT exclusivity
Novartis completes Sandoz Spin-off
Novartis completes Sandoz spin-off, focusing on innovative medicines
Sanofi and Teva collaborate on innovative IBD treatment
Hikma marks KLOXXADO two-year anniversary by surpassing 375,000 doses donated in the US
STADA seeks full approval for Kinpeygo in IgA nephropathy from UK MHRA
Azurity Pharmaceuticals completes Slayback Pharma acquisition
Sandoz secures European approval for Tyruko biosimilar in MS treatment
Senores Pharmaceuticals introduces Nicardipine Hydrochloride Capsules USP, 20mg and 30mg in US
Lupin collaborates with Mark Cuban Cost Plus Drug Company and COPD foundation
Certara Simcyp receives FDA grants for advanced pharmacokinetic modelling